Q-omics provides the consensus-scored THAP11 profile across patient tissues and cancer cell-line models. THAP11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, THAP11 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, THAP11 protein abundance shows 19,908 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, KIRC, and LUAD as cancer lineages where THAP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THAP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THAP11 survival associations across molecular data types. THAP11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THAP11 RNA expression–survival associations across cancer types. High THAP11 expression shows unfavorable associations in LIHC, ACC, KIRP and LAML, but favorable associations in UCEC and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for THAP11 RNA expression.
This table summarizes THAP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for THAP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THAP11 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, KIRP, LIHC and HNSC. The KIRC box plot shows higher THAP11 RNA expression in tumor versus normal tissue (log2 FC = +0.488, t-test p < 0.001).
This table shows molecular features associated with THAP11 in patient tissues and cancer cell lines. In patient samples, THAP11 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, THAP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
